Evidence map›Paper›PMID 33321791›Full record

ArticleJournal of personalized medicine2020

Equivocal PI-RADS Three Lesions on Prostate Magnetic Resonance Imaging: Risk Stratification Strategies to Avoid MRI-Targeted Biopsies.

Daniël F Osses, Christian Arsov, Lars Schimmöller, Ivo G Schoots, Geert J L H van Leenders, Irene Esposito, Sebastiaan Remmers, Peter Albers, Monique J Roobol

Open access · goldAbstract read
In one paragraph

Article in Journal of personalized medicine, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
0.9field-weighted citation impact, top 21% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 12 citations in OpenAlex.

  1. Article
  2. Article
  3. Precision medicine in prostate cancer: individualized treatment through radiomics, genomics, and biomarkers.Cancer imaging : the official publication of the International Cancer Imaging Society · 2025
    Review
  4. Article
  5. Article
  6. Article
  7. Observational
  8. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 2 institutions in 2 countries.

Daniël F OssesDepartment of Urology, Erasmus University Medical Center, 3015 GD Rotterdam, The Netherlands.
Christian ArsovMedical Faculty, Department of Urology, University Düsseldorf, D-40225 Düsseldorf, Germany.
Lars SchimmöllerMedical Faculty, Department of Diagnostic and Interventional Radiology, University Düsseldorf, D-40225 Düsseldorf, Germany.ORCID 0000-0001-7476-292X
Ivo G SchootsDepartment of Radiology & Nuclear Medicine, Erasmus University Medical Center, 3015 GD Rotterdam, The Netherlands.ORCID 0000-0002-9804-0603
Geert J L H van LeendersDepartment of Pathology, Erasmus University Medical Center, 3015 GD Rotterdam, The Netherlands.ORCID 0000-0003-2176-9102
Irene EspositoMedical Faculty, Department of Pathology, University Düsseldorf, D-40225 Düsseldorf, Germany.
Sebastiaan RemmersDepartment of Urology, Erasmus University Medical Center, 3015 GD Rotterdam, The Netherlands.ORCID 0000-0001-9530-6448
Peter AlbersMedical Faculty, Department of Urology, University Düsseldorf, D-40225 Düsseldorf, Germany.ORCID 0000-0002-1747-9615
Monique J RoobolDepartment of Urology, Erasmus University Medical Center, 3015 GD Rotterdam, The Netherlands.ORCID 0000-0001-6967-1708
Erasmus MC · NLHeinrich Heine University Düsseldorf · DE

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

We aimed to investigate the relation between largest lesion diameter, prostate-specific antigen density (PSA-D), age, and the detection of clinically significant prostate cancer (csPCa) using first-time targeted biopsy (TBx) in men with Prostate Imaging-Reporting and Data System (PI-RADS) 3 index lesions. A total of 292 men (2013-2019) from two referral centers were included. A multivariable logistic regression analysis was performed. The discrimination and clinical utility of the built model was assessed by the area under the receiver operation curve (AUC) and decision curve analysis, respectively. A higher PSA-D and higher age were significantly related to a higher risk of detecting csPCa, while the largest index lesion diameter was not. The discrimination of the model was 0.80 (95% CI 0.73-0.87). When compared to a biopsy-all strategy, decision curve analysis showed a higher net benefit at threshold probabilities of ≥2%. Accepting a missing ≤5% of csPCa diagnoses, a risk-based approach would result in 34% of TBx sessions and 23% of low-risk PCa diagnoses being avoided. In men with PI-RADS 3 index lesions scheduled for first-time TBx, the balance between the number of TBx sessions, the detection of low-risk PCa, and the detection of csPCa does not warrant a biopsy-all strategy. To minimize the risk of missing the diagnosis of csPCa but acknowledging the need of avoiding unnecessary TBx sessions and overdiagnosis, a risk-based approach is advisable.

Indexed as

clinically significant prostate cancerequivocal PI-RADS lesionsprostate MRIrisk stratificationtargeted biopsies

Identifiers

PMID33321791
PMCPMC7768373
OpenAlexW3113307796

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.